Pfizer Inc. and Merck & Co., Inc. both have a long heritage in the pneumococcal vaccines market and are simultaneously launching new offerings that are expected to deliver near- to mid-term vaccine franchise growth. With Pfizer's Prevnar 20 and Merck's Vaxneuvance, both companies are aiming to capture shares of the adult vaccine market, a big commercial opportunity though substantially smaller than the pediatric market.
ACIP Recommendations
- Prevnar 20 recommended for adults 65 and older and adults ages 19 to 64 with certain underlying medical conditions.
Now that the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has weighed in and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?